MedTrace Logo

Olmesartan Medoxomil and Diabetic Nephropathy

NCT00362960 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2006-10-09

No results posted yet for this study

Summary

Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy

Conditions

Interventions

DRUG

Olmesartan medoxomil

DRUG

Losartan

Sponsors & Collaborators

  • Sankyo Pharma Gmbh

    lead INDUSTRY

Principal Investigators

  • H Haller, MD · Hannover Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Completion
2004-09-30

Countries

  • Czechia
  • Estonia
  • Germany
  • Netherlands
  • Poland
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362960 on ClinicalTrials.gov